SMT202500034T1 - Uso di migalastat nel ridurre il rischio di evento cerebrovascolare in pazienti con malattia di fabry - Google Patents

Uso di migalastat nel ridurre il rischio di evento cerebrovascolare in pazienti con malattia di fabry

Info

Publication number
SMT202500034T1
SMT202500034T1 SM20250034T SMT202500034T SMT202500034T1 SM T202500034 T1 SMT202500034 T1 SM T202500034T1 SM 20250034 T SM20250034 T SM 20250034T SM T202500034 T SMT202500034 T SM T202500034T SM T202500034 T1 SMT202500034 T1 SM T202500034T1
Authority
SM
San Marino
Prior art keywords
migalostat
patients
risk
reducing
fabry disease
Prior art date
Application number
SM20250034T
Other languages
English (en)
Italian (it)
Inventor
Nina Skuban
Hjalmar Lagast
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69726736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202500034(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of SMT202500034T1 publication Critical patent/SMT202500034T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
SM20250034T 2019-01-22 2020-01-22 Uso di migalastat nel ridurre il rischio di evento cerebrovascolare in pazienti con malattia di fabry SMT202500034T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795524P 2019-01-22 2019-01-22
EP20708283.5A EP3914247B1 (en) 2019-01-22 2020-01-22 Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease
PCT/US2020/014531 WO2020154354A1 (en) 2019-01-22 2020-01-22 Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease

Publications (1)

Publication Number Publication Date
SMT202500034T1 true SMT202500034T1 (it) 2025-03-12

Family

ID=69726736

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20250034T SMT202500034T1 (it) 2019-01-22 2020-01-22 Uso di migalastat nel ridurre il rischio di evento cerebrovascolare in pazienti con malattia di fabry

Country Status (17)

Country Link
US (1) US20220087993A1 (enExample)
EP (2) EP4523750A3 (enExample)
JP (2) JP7680356B2 (enExample)
AR (1) AR117861A1 (enExample)
DK (1) DK3914247T3 (enExample)
ES (1) ES3007212T3 (enExample)
FI (1) FI3914247T3 (enExample)
HR (1) HRP20250078T1 (enExample)
HU (1) HUE069934T2 (enExample)
LT (1) LT3914247T (enExample)
PL (1) PL3914247T3 (enExample)
PT (1) PT3914247T (enExample)
RS (1) RS66410B1 (enExample)
SI (1) SI3914247T1 (enExample)
SM (1) SMT202500034T1 (enExample)
TW (1) TW202042812A (enExample)
WO (1) WO2020154354A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3840753T (lt) * 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2018017721A1 (en) * 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients

Also Published As

Publication number Publication date
HUE069934T2 (hu) 2025-04-28
ES3007212T3 (en) 2025-03-19
LT3914247T (lt) 2025-01-27
EP3914247A1 (en) 2021-12-01
EP4523750A2 (en) 2025-03-19
PT3914247T (pt) 2025-01-23
JP2022518733A (ja) 2022-03-16
FI3914247T3 (fi) 2025-02-16
RS66410B1 (sr) 2025-02-28
US20220087993A1 (en) 2022-03-24
WO2020154354A1 (en) 2020-07-30
PL3914247T3 (pl) 2025-04-14
EP4523750A3 (en) 2025-06-11
SI3914247T1 (sl) 2025-03-31
AR117861A1 (es) 2021-09-01
JP2025128105A (ja) 2025-09-02
HRP20250078T1 (hr) 2025-03-28
EP3914247B1 (en) 2024-11-13
JP7680356B2 (ja) 2025-05-20
DK3914247T3 (da) 2025-01-27
TW202042812A (zh) 2020-12-01

Similar Documents

Publication Publication Date Title
GB201900797D0 (en) Use of cannabinoids in the treatment of comorbidities associated with epilepsy
LT4014976T (lt) Aprocitentanas, skirtas panaudoti derinyje su valsartanu, gydant hipertenziją ir su ja susijusias ligas
IL264301A (en) Treatment of Fabry disease in ert-naive and ert-experienced patients
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
IL246579A0 (en) Compounds that inhibit the activity of 2lrrk and their use in the treatment of Parkinson's disease
HUE065152T2 (hu) Fluor-fenil-béta-hidroxietilaminok és alkalmazásuk hiperglikémia kezelésében
ES3065184T3 (en) Use of migalastat for treating fabry disease in pregnant patients
IL272893A (en) Methods for increasing and/or stabilizing cardiac functions in patients with Fabry disease
IL289167A (en) The history of 2h-indazole and their use in the treatment of diseases
IL273470A (en) Semaglutide in medical treatment
HUE064761T2 (hu) Klasszikus FABRY-betegségben szenvedõ betegek kezelése migalasztáttal
SG11202000423XA (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
LT3914247T (lt) Migalostato vartojimas mažinant smegenų kraujotakos sutrikimo riziką pacientams, sergantiems fabri liga
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
SG11202103806VA (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
PL3352777T3 (pl) Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona
IL270788A (en) Sulfonylurea compounds in the treatment of disease associated with uv-induced damage
EP3661494B8 (en) Use of tasimelteon for the treatment of affective disorders in majority black african patients
GB202011126D0 (en) Use of cannabidiol in the treatment of sezures associated with mutifocal epilepsy
GB2572652B (en) Improvements in bedside assist handrails and their attachment
IL284074A (en) Decorin for use in the treatment of diabetes
GB201817442D0 (en) Improvements in bedside assist handrails and their attachment
GB201902087D0 (en) Medicament and the use thereof
GB201802743D0 (en) Medicament and use thereof
GB201503897D0 (en) Modifying the body's physiological and psychological response to alcohol